Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
27.79
-0.70 (-2.46%)
Jul 16, 2026, 4:00 PM EDT - Market closed
Cue Biopharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 16.38 | 27.14 | 22.46 | 48.51 | 51.61 | 64.37 |
Short-Term Investments | - | - | - | - | 24.68 | - |
Cash & Short-Term Investments | 16.38 | 27.14 | 22.46 | 48.51 | 76.29 | 64.37 |
Cash Growth | 24.69% | 20.82% | -53.71% | -36.41% | 18.52% | -24.15% |
Accounts Receivable | 5.35 | 5.55 | 0.95 | 1.7 | 0.06 | 3.14 |
Other Receivables | 1.9 | 1.9 | - | - | - | - |
Total Trade Receivables | 7.25 | 7.45 | 0.95 | 1.7 | 0.06 | 3.14 |
Other Current Assets | 2.76 | 2.4 | 1.73 | 1.24 | 0.84 | 0.95 |
Total Current Assets | 26.39 | 36.98 | 25.14 | 51.45 | 77.19 | 68.47 |
Net Property, Plant & Equipment | 3.61 | 4.32 | 4.84 | 7.12 | 10.7 | 11.92 |
Other Long-Term Assets | 0.88 | 0.91 | 2.21 | 2.96 | 3.39 | 3.01 |
Total Assets | 30.88 | 42.21 | 32.19 | 61.53 | 91.28 | 83.4 |
Accounts Payable | 3.33 | 3.95 | 2.82 | 3.5 | 2.73 | 2.59 |
Accrued Expenses | 1.5 | 1.61 | 2.91 | 4.14 | 3.55 | 4.62 |
Current Portion of Long-Term Debt | - | - | 4.33 | 3.96 | 1.96 | - |
Current Portion of Leases | 1.56 | 1.91 | 3.54 | 3.37 | 3.3 | 4.93 |
Unearned Revenue | - | 5.34 | 0.09 | 2.11 | - | 0.65 |
Other Current Liabilities | 1 | 0.69 | - | - | - | - |
Total Current Liabilities | 7.39 | 13.49 | 13.69 | 17.08 | 11.55 | 12.79 |
Long-Term Debt | - | - | - | 4.2 | 8.04 | - |
Long-Term Leases | 1.88 | 2.29 | 1 | 3.16 | 6.02 | 5.12 |
Total Long-Term Liabilities | 1.88 | 2.29 | 1 | 7.36 | 14.05 | 5.12 |
Total Liabilities | 9.27 | 15.78 | 14.69 | 24.45 | 25.6 | 17.91 |
Common Stock | 0 | 0.1 | 0.06 | 0.05 | 0.04 | 0.03 |
Additional Paid-in Capital | 395.25 | 394.8 | 359.3 | 338.23 | 316.19 | 262.91 |
Accumulated Other Comprehensive Income | - | - | - | - | -0.1 | - |
Retained Earnings | -373.64 | -368.47 | -341.86 | -301.19 | -250.46 | -197.45 |
Shareholders' Equity | 21.61 | 26.43 | 17.5 | 37.09 | 65.68 | 65.49 |
Total Liabilities & Equity | 30.88 | 42.21 | 32.19 | 61.53 | 91.28 | 83.4 |
Total Debt | 3.44 | 4.2 | 8.88 | 14.7 | 19.32 | 10.05 |
Net Cash (Debt) | 12.94 | 22.94 | 13.58 | 33.82 | 56.97 | 54.32 |
Net Cash Growth | -43.59% | 68.88% | -59.84% | -40.64% | 4.89% | -30.11% |
Net Cash Per Share | 3.44 | 7.26 | 7.23 | 22.17 | 47.95 | 52.09 |
Book Value | 21.61 | 26.43 | 17.5 | 37.09 | 65.68 | 65.49 |
Book Value Per Share | 5.75 | 8.37 | 9.32 | 24.32 | 55.27 | 62.80 |
Tangible Book Value | 21.61 | 26.43 | 17.5 | 37.09 | 65.68 | 65.49 |
Tangible Book Value Per Share | 5.75 | 8.37 | 9.32 | 24.32 | 55.27 | 62.80 |